Contribute Try STAT+ Today

After Mylan shareholders last week rebuked the drug maker by voting against executive compensation, three large pension funds are now calling for Mylan to remove its non-executive chairman and a director in hopes of restoring confidence in the beleaguered board.

In explaining their reasoning, the funds pointed to an “astounding” 83.5 percent of shareholders who did not support executive pay, including a controversial, $97 million package given to non-executive chairman Robert Coury. The funds also noted that a majority of shareholders – 56 percent – voted against re-electing Wendy Cameron, the director who heads the Mylan compensation committee (the numbers are right here).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.